SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Developmentally programmed pediatric sarcomas: a versatile platform for drug discovery and molecular precision medicine

The project aims to develop innovative in vitro and in vivo models of Ewing sarcoma using human pluripotent stem cells to enhance drug discovery and precision medicine for pediatric cancers.

Subsidie
€ 1.999.124
2023

Projectdetails

Introduction

Pediatric sarcomas account for ~20% of childhood cancers. They have disappointing survival rates, with very little therapeutic progress over the last three decades. We clearly have to rethink the science and find new ways to tackle these devastating tumors. I propose that new cellular models are needed that account for the developmental origins of pediatric sarcoma, in order to accelerate drug discovery and molecular precision medicine.

Focus on Ewing Sarcoma

Focusing on Ewing sarcoma, which is a developmental cancer caused by a (known) fusion oncogene expressed in (unknown) cells-of-origin, we will pursue a “build it to understand it” approach and construct in vitro and in vivo tumor models starting from human pluripotent stem cells (hPSCs).

Model Validation

We will validate these models against our single-cell and spatial maps of Ewing sarcoma tumors, and we will pursue initial applications in academic drug discovery, including:

  1. Targeting the regulatory programs of Ewing sarcoma cells
  2. Investigating metabolic dependencies of the tumor microenvironment
  3. Studying developmentally programmed tumors in their in vivo context

Building Ewing Sarcoma Models

To build Ewing sarcoma models in a molecularly defined manner, we will:

  1. Map oncogene-competent cell states by inducing EWS-FLI1 expression in hPSC-based models of human development (Aim 1).
  2. Create supportive tumor microenvironments by 3D differentiation and CRISPR screening in stromal cells (Aim 2).
  3. Evaluate the ability of in vitro models to form tumors in mice, and pursue full in vivo modeling of Ewing sarcoma using genetically engineered teratomas (Aim 3).

Comparison with Existing Models

Compared to patient-derived xenografts, organoids, or cell lines, our approach captures early events of tumorigenesis, providing complementary in vitro and in vivo models of Ewing sarcoma for biomedical and translational research.

Generalization to Other Tumor Types

This approach will generalize to other tumor types, as it takes the concept of developmental cancers seriously and operationalizes it using cellular programming and high-throughput functional biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.124
Totale projectbegroting€ 1.999.124

Tijdlijn

Startdatum1-10-2023
Einddatum30-9-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • ST. ANNA KINDERKREBSFORSCHUNG GMBHpenvoerder

Land(en)

Austria

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

ERC Consolid...€ 2.000.000
2025
Details

Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide

This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.

ERC Consolid...€ 1.992.235
2024
Details

Oncogenic competence during development – When, Where and Why?

This project aims to uncover the origins and transformation mechanisms of malignant rhabdoid tumors through advanced genomic and imaging techniques, with the goal of developing targeted treatments.

ERC Starting...€ 1.499.943
2023
Details

Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma

This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.

ERC Consolid...€ 2.000.000
2024
Details

Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastoma

This project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity.

ERC Starting...€ 1.497.981
2024
Details
ERC Consolid...

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

ERC Consolidator Grant
€ 2.000.000
2025
Details
ERC Consolid...

Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide

This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.

ERC Consolidator Grant
€ 1.992.235
2024
Details
ERC Starting...

Oncogenic competence during development – When, Where and Why?

This project aims to uncover the origins and transformation mechanisms of malignant rhabdoid tumors through advanced genomic and imaging techniques, with the goal of developing targeted treatments.

ERC Starting Grant
€ 1.499.943
2023
Details
ERC Consolid...

Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma

This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.

ERC Consolidator Grant
€ 2.000.000
2024
Details
ERC Starting...

Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastoma

This project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity.

ERC Starting Grant
€ 1.497.981
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.

EIC Transition€ 2.433.125
2022
Details
EIC Transition

Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.

EIC Transition
€ 2.433.125
2022
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.